Company intelligence
Pharmaron
Global Life Sciences Services Provider
About Pharmaron
Pharmaron: Global Life Sciences Services Provider Stock Code: 300759.SZ/3759.HK Founded in 2004, Pharmaron is a premier life sciences service provider that offers a broad spectrum of research, development, and manufacturing service capabilities throughout the entire drug discovery, preclinical, and clinical development process across multiple therapeutic modalities, including small molecules, biologics, and CGT products. Pharmaron’s Comprehensive CRO & CDMO Services • Synthetic, Medicinal, and Analytical Chemistry Services • Biology Services (e.g., in vitro screening, structural biology, biomarkers) • DMPK Services (e.g., in vitro ADME, in vivo PK, PKPD, mass balance) • Pharmacology Services (e.g., in vivo pharmacology, animal disease models, immunotoxicity) • Drug Safety Assessment Services (e.g., toxicology, safety pharmacology, genetic toxicology) • Radiochemistry and Isotopically Labelled Metabolism Services (e.g., 14C/Carbon-14 radiosynthesis, 3H/tritium radiosynthesis, QWBA, mARG) • CMC Services (e.g., API manufacturing, process chemistry, formulation development) • Clinical Development Services (e.g., First-in-Human [FIH], ethnobridging, microdosing Phase 0, absolute bioavailability) Commitment to Excellence and Innovation With a proven track record of success, Pharmaron continually invests in its people, facilities, and technologies to meet evolving scientific and regulatory demands. The company prides itself on enabling scientific breakthroughs and supporting its partners in advancing human health. ____________________________________ Learn More: Explore Pharmaron’s services to discover how to accelerate your R&D programs. www.pharmaron.com. ________________________________________ Keywords: CRO, CDMO, synthetic chemistry, medicinal chemistry, biology, radiochemistry, toxicology, First-in-Human, API manufacturing, PKPD, 14C radiosynthesis, discovery biologics, clinical development, small molecules, biologics, cell and gene therapy (CGT) products
Verified activity
Signals from Pharmaron
17 published signals
Research & Knowledge
Pharmaron published data showing that DMSO and MeOH significantly inhibit AChE and BChE activity in inhibition assays.
Reported by Pharmaron
Research & Knowledge
Pharmaron published an ebook exploring comprehensive preclinical study design for ocular gene therapy, vector characterization, and regulatory-aligned development approaches.
Reported by Pharmaron
Presence & Recognition
Pharmaron is hosting an upcoming webinar titled What Makes a Good ADME Study? Key Considerations for Radiolabelled and 14C Studies on 22 September 2026 at 8 am PT / 11 am ET / 4 pm BST.
Reported by Pharmaron
Presence & Recognition
Pharmaron is attending the NLSdays event in Stockholm to discuss integrated CRO and CDMO services for program advancement from discovery to commercialisation.
Reported by Pharmaron
Presence & Recognition
Pharmaron is connecting with the pharma community at CPHI Milan to build stronger partnerships and unlock more potential together.
Reported by Erik Kataisto
Presence & Recognition
Pharmaron participated in the NLSdays event in Stockholm, showcasing its comprehensive CRO and CDMO capabilities alongside a pleasant culture.
Reported by Filipa Antunes
People
Pharmaron UK is hiring for a position within the ADME/PK lab to move out of the ADME/PK lab into a more commercially aligned role.
Reported by Tim Smith
People
Pharmaron is recruiting for a Scientific BD Proposals Coordinator – Discovery ADME/PK to join the company in Hoddesdon.
Reported by Ingrid Lebleu (🟢🟡🔵🔴)
Presence & Recognition
Pharmaron is sponsoring the Boston Pharmaceutical & BioScience Society (PBSS) workshop on September 9th in Cambridge, Massachusetts, focused on IND filing and nonclinical considerations for emerging modalities.
Reported by Pharmaron
Presence & Recognition
Pharmaron is hosting a conference titled #6C42 at Feria Miliana from October 6 to 8, 2026.
Reported by Pharmaron
Products & Services
Pharmaron published a preclinical services brochure featuring its preclinical capabilities spanning first-in-animal studies through GLP, surgical and imaging-based research, complex medical device testing, and regulatory-aligned study design.
Reported by Scott Barnhill
Presence & Recognition
Pharmaron is attending ISSX North America 2026 in San Francisco to showcase new research across ADME, bioanalysis, translational sciences, modelling, permeability, hepatotoxicity, oral peptide delivery, microphysiological systems, and radiolabelled ADME studies at Booth #310.
Reported by Pharmaron
Products & Services
Pharmaron supports developers with comprehensive, regulatory-aligned preclinical services from first-in-animal to GLP studies.
Reported by Pharmaron
Research & Knowledge
Pharmaron published a research paper in Chemical Science in collaboration with Professor Craig Johnston and the University of St Andrews showcasing a sustainable photochemical approach to synthesising tetrahydroquinolines.
Reported by Pharmaron
People
Pharmaron is hiring Industrial Placement Students in the Process Chemistry department for 2027/28 placements at the Hoddesdon site.
Reported by Matthew Lloyd
Presence & Recognition
Pharmaron is supporting the San Diego Walk to Defeat ALS, with the team coming together on October 3rd to walk, raise awareness, and support the ALS community.
Reported by Manny Chavez
Products & Services
Pharmaron's specialized CGT Ophthalmology platform brings targeted disease models, integrated analysis, and deep expertise to help sponsors navigate the path toward First-in-Human trials.
Reported by Scott Barnhill